Syndax Pharmaceuticals Inc (SNDX) Given Consensus Rating of “Buy” by Brokerages

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) has been assigned an average recommendation of “Buy” from the eight research firms that are currently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $29.00.

Several research analysts have recently issued reports on the company. ValuEngine upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, July 6th. Zacks Investment Research upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 15th. Finally, HC Wainwright began coverage on Syndax Pharmaceuticals in a report on Thursday, July 12th. They set a “buy” rating and a $30.00 target price on the stock.

Shares of Syndax Pharmaceuticals traded down $0.31, hitting $7.04, during midday trading on Tuesday, according to Marketbeat. The stock had a trading volume of 205,962 shares, compared to its average volume of 290,200. Syndax Pharmaceuticals has a fifty-two week low of $6.10 and a fifty-two week high of $15.20.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.13. Syndax Pharmaceuticals had a negative return on equity of 80.35% and a negative net margin of 3,190.51%. The business had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.38 million. equities research analysts expect that Syndax Pharmaceuticals will post -3.21 EPS for the current year.

Institutional investors have recently modified their holdings of the company. Rhumbline Advisers bought a new stake in shares of Syndax Pharmaceuticals in the second quarter valued at about $103,000. The Manufacturers Life Insurance Company increased its position in shares of Syndax Pharmaceuticals by 266.9% in the first quarter. The Manufacturers Life Insurance Company now owns 10,566 shares of the company’s stock valued at $151,000 after acquiring an additional 7,686 shares during the last quarter. Sofinnova Ventures Inc acquired a new stake in shares of Syndax Pharmaceuticals in the first quarter valued at about $173,000. Spark Investment Management LLC acquired a new stake in shares of Syndax Pharmaceuticals in the second quarter valued at about $198,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Syndax Pharmaceuticals in the fourth quarter valued at about $225,000. Institutional investors own 69.72% of the company’s stock.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.

Recommended Story: Book Value Per Share – BVPS

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply